News >

Tackling Challenging Patient Populations in DLBCL

Laura Panjwani
Published: Thursday, Jan 21, 2016

Kathryn Kolibaba, MD

Kathryn Kolibaba, MD

There is a misconception that diffuse large B-cell lymphoma (DLBCL) is often a more favorable diagnosis than other types of non-Hodgkin lymphoma, says Kathryn Kolibaba, MD, medical oncology/hematology, Compass Oncology, and co-chair, Hematology Research Committee, US Oncology Research.

“I don’t think everyone in community oncology understands that there are subtypes of diffuse large B-cell lymphoma, and that only a minority of patients have those favorable outcomes you hear about,” says Kolibaba. “Our efforts need to be ongoing to look for the best way to treat patients who are not germinal center B-cell (GCB) or young and healthy.”

Two recent studies that Kolibaba is involved with are assessing patients who typically have less favorable outcomes. The first, which is an ongoing dose-escalation study, is investigating the antibody-drug conjugate polatuzumab vedotin combined with R-CHOP in high-risk patients with previously untreated DLBCL. Thus far, results have been promising.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication